Invivyd (NASDAQ:IVVD) CFO William Duke Sells 22,355 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) CFO William Duke sold 22,355 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $0.72, for a total transaction of $16,095.60. Following the completion of the transaction, the chief financial officer owned 187,362 shares in the company, valued at $134,900.64. The trade was a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Stock Performance

Shares of Invivyd stock traded up $0.13 on Tuesday, hitting $0.87. 7,732,095 shares of the company’s stock were exchanged, compared to its average volume of 3,061,089. The company has a 50-day simple moving average of $0.77 and a 200-day simple moving average of $1.23. The stock has a market capitalization of $255.75 million, a PE ratio of -2.63 and a beta of 0.71. Invivyd, Inc. has a 1 year low of $0.48 and a 1 year high of $3.07.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The company had revenue of $14.29 million during the quarter, compared to analysts’ expectations of $14.40 million. On average, analysts expect that Invivyd, Inc. will post -0.52 EPS for the current fiscal year.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Institutional Trading of Invivyd

Several institutional investors have recently made changes to their positions in the business. United Capital Financial Advisors LLC bought a new stake in Invivyd during the 2nd quarter valued at approximately $84,000. Bank of America Corp DE purchased a new position in Invivyd in the 2nd quarter worth approximately $311,000. Jupiter Topco LLC bought a new position in Invivyd in the 2nd quarter worth approximately $30,048,000. ADAR1 Capital Management LLC bought a new position in Invivyd in the 2nd quarter worth approximately $3,322,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Invivyd during the 2nd quarter valued at approximately $52,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Wall Street Analyst Weigh In

IVVD has been the subject of a number of analyst reports. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. Finally, HC Wainwright reissued a “buy” rating on shares of Invivyd in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Invivyd currently has a consensus rating of “Hold” and an average price target of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.